Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Total Liabilities (2016 - 2025)

Tg Therapeutics (TGTX) has 10 years of Total Liabilities data on record, last reported at $415.2 million in Q4 2025.

  • For Q4 2025, Total Liabilities rose 16.86% year-over-year to $415.2 million; the TTM value through Dec 2025 reached $415.2 million, up 16.86%, while the annual FY2025 figure was $415.2 million, 16.86% up from the prior year.
  • Total Liabilities reached $415.2 million in Q4 2025 per TGTX's latest filing, down from $417.8 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $426.2 million in Q2 2025 and bottomed at $98.2 million in Q3 2021.
  • Average Total Liabilities over 5 years is $225.0 million, with a median of $169.5 million recorded in 2023.
  • Peak YoY movement for Total Liabilities: decreased 5.26% in 2022, then soared 136.84% in 2024.
  • A 5-year view of Total Liabilities shows it stood at $142.5 million in 2021, then decreased by 5.26% to $135.0 million in 2022, then grew by 25.26% to $169.1 million in 2023, then surged by 110.15% to $355.3 million in 2024, then grew by 16.86% to $415.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Liabilities were $415.2 million in Q4 2025, $417.8 million in Q3 2025, and $426.2 million in Q2 2025.